Dergiler / Annals of Medical Research / 2020 / Cilt: 27 - Sayı: 12

Evaluation of HLA-B* 57:01 and its effect on antiretroviral therapy in patients with human immunodeficiency virus infection: Experience of a University Hospital

Sayfa
3050–3053
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The fact that this procedure can be performed in centers following HIV-infected patientswill positively affect the process of starting treatment.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: Before the decision to start abacavir (ABC), which is a member of the antiretroviral therapy (ART) combinations, the presenceof the HLA-B*57:01 allele gene should be investigated in case of hypersensitivity to the drug.In recent years, many clinics tend to conduct “treat now” policy for HIV therapy.
📊
Temel Bulgular & Veri:We aimed to evaluate HLA-B*57:01 test results andits effect on the initiation time of ART, combination and changing of ART.Materials and Methods: HLA-B*57:01 screening test was evaluated retrospectively in the HIV-infected patients admitted to InonuUniversity Faculty of Medicine Department of Infectious Diseases and Clinical Microbiology between January 2019 and December2019.Moreover, the time frame of HLA-B*57:01 tests were evaluated along with the HIV confirmation test completion time.
💡
Sonuç & Katkı:The fact that this procedure can be performed in centers following HIV-infected patientswill positively affect the process of starting treatment.
🔬Tür:Araştırma Makalesi
📍Kapsam:2019 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Aim: Before the decision to start abacavir (ABC), which is a member of the antiretroviral therapy (ART) combinations, the presenceof the HLA-B*57:01 allele gene should be investigated in case of hypersensitivity to the drug.In recent years, many clinics tend to conduct “treat now” policy for HIV therapy. We aimed to evaluate HLA-B*57:01 test results andits effect on the initiation time of ART, combination and changing of ART.Materials and Methods: HLA-B*57:01 screening test was evaluated retrospectively in the HIV-infected patients admitted to InonuUniversity Faculty of Medicine Department of Infectious Diseases and Clinical Microbiology between January 2019 and December2019.Moreover, the time frame of HLA-B*57:01 tests were evaluated along with the HIV confirmation test completion time. It was evaluatedwhether there was any effect on the start of treatment and treatment change.Results: Of the 47 HIV-positive patients 44 (93.6%) were male and 3 (6.4%) were female whose HLA-B*57:01 allele was screened.The mean age ± SD of these 47 patients was 37.7 ± 13.5 years. HLA-B*57:01 gene positivity was not detected in any of our cases.After HLA-B*57:01 test detection, ten (21%) of these patients were treated with ABC sulfate plus dolutegravir sodium plus lamivudine.Five of the patients were naive patients, while the other five patients were treatment experienced.HLA-B*57: 01 allele test completion time of the patients (mean ± SD) was 4.02 ± 2.35 days. HLA-B*57:01 completion time did notdiffer statistically in patients with and without treatment change (p=0.243).Conclusion: HIV infected individuals should be started to treat with ART soon after their diagnosis. To detect the HLA-B*57:01 allelein genomic DNA is important in this period. The fact that this procedure can be performed in centers following HIV-infected patientswill positively affect the process of starting treatment.

🔖

Bu Makaleye Atıf Yap

BAYINDIR, Y., TOPLU, S. A., KÖSE, A., ERSOY, Y., MEMİSOGLU, F., OTLU, G. (2022). Evaluation of HLA-B* 57:01 and its effect on antiretroviral therapy in patients with human immunodeficiency virus infection: Experience of a University Hospital. Annals of Medical Research, Cilt: 27 - Sayı: 12, 3050–3053. https://ajindex.com/articles/446581

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Gunthard HF, Saag MS, Benson CA, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA 2016
  2. 2019 fact sheet. https://www.unaids.org/ Global HIV & AIDS statistics 3. Sterne JA, Hernán MA, Ledergerber B, et al. Longterm effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005
  3. Martin MA, Klein TE, Dong BJ, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and ABC dosing. Clin Pharmacol Ther 2012
  4. UK Collaborative HIV Cohort Study Steering Committee. HLA- B* 5701 status, disease progression, and response to antiretroviral therapy. AIDS. 2013
  5. Phillips KA, Veenstra D, Van Bebber S, et al. An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics. Pharmacogenomics 2003
  6. Hughes DA, Javier VF, Ward CC, et al. Costeffectiveness analysis of HLA B*5701 genotyping in preventing ABC hypersensitivity. Pharmacogenetics 2004
  7. Stainsby CM, Perger TM, Vannappagari V, et al. ABC Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B* 5701 Screening as a Risk-Mitigation Measure. Pharmacotherapy 2019
  8. Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-B* 5701 as a marker for immunologically confirmed ABC hypersensitivity in white and black patients. Clin Infect Dis 2008
  9. Zhang H, Zhang T, Zhao H, et al. Low prevalence of human leukocyte antigen-B*5701 in HIV-1-infected Chinese subjects: a prospective epidemiological investigation. AIDS Res Ther 2015
  10. Pynka ML, Aksak-Wąs B, Urbańska A, et al. Protective Effect of HLA-B* 5701 and HLA-C -35 Genetic Variants in HIV-Positive Caucasians from Northern Poland. PLoS ONE 2015
  11. e0127867 12. Araújo C, Carvalho CV, Souza Freire MF, Yet al. Prevalence of Human Leukocyte Antigen HLA-B* 5701 in HIV-1 Infected Individuals in Brazil. J Genet 2014
  12. Deveci A, Çoban AY, Durupınar B. HIV ile Enfekte Hastalarda İnsan Lökosit Antijeni (HLA)-B* 57:01 Prevalansı. Mikrobiyol Bul 2016
  13. Inan D, Sayan M, Deveci A, et al. HLA-B*57:01 Allele Prevalence in Turkish HIV Infected Patients and the value of Real-Time PCR Allele Testing Compored with Sequence Specific Primer Technique. HIV Drug Therapy 2020. 15. The UK Collaborative HIV Cohort Study Steering C